Assignee
FIVE PRIME THERAPEUTICS INC
US·53 granted patents·51 pending applications·208 citations·filing 2005–2025
Top patents by PatentIndex Score
104 records- 0197US7678890B2Compositions and methods of treating disease with FGFR fusion proteinsFIVE PRIME THERAPEUTICS INC·Filed 2006·Granted Mar 16, 2010·67 cites·3 claims
- 0295US11155615B2Anti-ROR1 antibodiesFIVE PRIME THERAPEUTICS INC·Filed 2016·Granted Oct 26, 2021·13 cites·13 claims
- 0395US9765147B2Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancerFIVE PRIME THERAPEUTICS INC·Filed 2015·Granted Sep 19, 2017·25 cites·31 claims
- 0495US7982014B2FGFR3-IIIc fusion proteinsFIVE PRIME THERAPEUTICS INC·Filed 2010·Granted Jul 19, 2011·24 cites·12 claims
- 0592US10221244B2Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancerFIVE PRIME THERAPEUTICS INC·Filed 2017·Granted Mar 5, 2019·10 cites·31 claims
- 0691US11306144B2B7-H4 antibodies and methods of use thereofFIVE PRIME THERAPEUTICS INC·Filed 2018·Granted Apr 19, 2022·6 cites·45 claims
- 0790US11814431B2B7-H4 antibodies and methods of use thereofFIVE PRIME THERAPEUTICS INC·Filed 2020·Granted Nov 14, 2023·3 cites·48 claims
- 0889US9957327B2Antibodies that bind colony stimulating factor 1 receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2016·Granted May 1, 2018·5 cites·24 claims
- 0989US7776564B2Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of useFIVE PRIME THERAPEUTICS INC·Filed 2005·Granted Aug 17, 2010·15 cites·13 claims
- 1088US10618967B2Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancerFIVE PRIME THERAPEUTICS INC·Filed 2019·Granted Apr 14, 2020·5 cites·31 claims
- 1186US10273281B2CD80 extracellular domain polypeptides and their use in cancer treatmentFIVE PRIME THERAPEUTICS INC·Filed 2016·Granted Apr 30, 2019·7 cites·40 claims
- 1284US10172937B2Method of treatment of malignant solid tumors with afucosylated anti-FGFR2IIIb antibodiesFIVE PRIME THERAPEUTICS INC·Filed 2016·Granted Jan 8, 2019·5 cites·32 claims
- 1383US11091555B2Method of treating gastric cancer with anti-FGFR2-IIIb antibodies and modified FOLFOX6 chemotherapyFIVE PRIME THERAPEUTICS INC·Filed 2018·Granted Aug 17, 2021·3 cites·20 claims
- 1482US7795404B1Human soluble notch receptor ligandsFIVE PRIME THERAPEUTICS INC·Filed 2007·Granted Sep 14, 2010·8 cites·14 claims
- 1581US10221243B2Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2016·Granted Mar 5, 2019·4 cites·23 claims
- 1681US2024043542A1B7-h4 antibodies and methods of use thereofFIVE PRIME THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1781US2025206822A1Antibodies Binding to Vista at Acidic pHFIVE PRIME THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1881US2023212299A1Anti-CSF1R Antibody and Anti-PD-1 Antibody Combination Therapy for CancerFIVE PRIME THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1980US2022153851A1Antibodies that Bind Colony Stimulating Factor 1 Receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2079US12195535B2Antibodies binding to VISTA at acidic pHFIVE PRIME THERAPEUTICS INC·Filed 2023·Granted Jan 14, 2025·0 cites·37 claims
- 2178US12365719B2CD80 extracellular domain polypeptides and their use in cancer treatmentFIVE PRIME THERAPEUTICS INC·Filed 2022·Granted Jul 22, 2025·0 cites·18 claims
- 2277US12173069B2Antibodies binding to vista at acidic pHFIVE PRIME THERAPEUTICS INC·Filed 2019·Granted Dec 24, 2024·1 cites·28 claims
- 2376US12435136B2Antibodies binding to ILT4FIVE PRIME THERAPEUTICS INC·Filed 2022·Granted Oct 7, 2025·0 cites·42 claims
- 2476US10730949B2Method of treating PVNS with anti-CSF1R antibodiesFIVE PRIME THERAPEUTICS INC·Filed 2018·Granted Aug 4, 2020·1 cites·35 claims
- 2575US12465636B2Method of making afucosylated anti-FGFR2IIIB antibodiesFIVE PRIME THERAPEUTICS INC·Filed 2021·Granted Nov 11, 2025·0 cites·13 claims
- 2675US10040858B2Anti-CSF1R antibodies for treating PVNSFIVE PRIME THERAPEUTICS INC·Filed 2015·Granted Aug 7, 2018·2 cites·56 claims
- 2775US9200075B2Nucleic acids encoding antibodies that bind colony stimulating factor 1 receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2014·Granted Dec 1, 2015·1 cites·23 claims
- 2875US2024317864A1B7-h4 antibody dosing regimensFIVE PRIME THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2975US2025129166A1Antibodies Binding to Vista at Acidic pHFIVE PRIME THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3074US11186646B2Antibodies that bind colony stimulating factor 1 receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2020·Granted Nov 30, 2021·0 cites·19 claims
- 3174US10982001B2Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2016·Granted Apr 20, 2021·1 cites·17 claims
- 3273US2009286954A1Human cDNA Clones Comprising Polynucleotides Encoding Polypeptides and Methods of Their UseFIVE PRIME THERAPEUTICS INC·Filed 2009·Application pending·0 cites
- 3372US2023013293A1B7-h4 antibodies and methods of use thereofFIVE PRIME THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3471US11566076B2Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancersFIVE PRIME THERAPEUTICS INC·Filed 2020·Granted Jan 31, 2023·0 cites·25 claims
- 3571US11098103B2CD80 extracellular domain polypeptides and their use in cancer treatmentFIVE PRIME THERAPEUTICS INC·Filed 2019·Granted Aug 24, 2021·0 cites·8 claims
- 3670US2008182974A1Human cDNA clones comprising polynucleotides encoding polypeptides and methods of their useFIVE PRIME THERAPEUTICS INC·Filed 2007·Application pending·0 cites
- 3769US10562970B2Antibodies that bind colony stimulating factor 1 receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2018·Granted Feb 18, 2020·0 cites·28 claims
- 3869US9775881B2Methods of treating mesothelioma by administration of compounds comprising FGFR1 ECDFIVE PRIME THERAPEUTICS INC·Filed 2014·Granted Oct 3, 2017·1 cites·19 claims
- 3969US2023287123A1B7-h4 antibody dosing regimensFIVE PRIME THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4069US2026085123A1Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatmentFIVE PRIME THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4169US2023052212A1Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatmentFIVE PRIME THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4269US2025269016A1Afucosylated Anti-FGFR2IIIB AntibodiesFIVE PRIME THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4368US10822421B2Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2019·Granted Nov 3, 2020·0 cites·37 claims
- 4468US2015203566A1Fgfr1 extracellular domain combination therapiesFIVE PRIME THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 4567US12319738B2Anti-FGFR2 antibodies in combination with chemotherapy agents in gastric cancerFIVE PRIME THERAPEUTICS INC·Filed 2021·Granted Jun 3, 2025·0 cites·12 claims
- 4667US9475871B2Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteinsFIVE PRIME THERAPEUTICS INC·Filed 2014·Granted Oct 25, 2016·0 cites·22 claims
- 4766US11235059B2Afucosylated anti-FGFR2IIIB antibodiesFIVE PRIME THERAPEUTICS INC·Filed 2018·Granted Feb 1, 2022·0 cites·59 claims
- 4866US10975153B2Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2015·Granted Apr 13, 2021·1 cites·29 claims
- 4966US9192683B2Methods of treating disease with FGFR1 fusion proteinsFIVE PRIME THERAPEUTICS INC·Filed 2013·Granted Nov 24, 2015·0 cites·21 claims
- 5066US2021277130A1Methods of Treating Conditions with Antibodies that Bind Colony Stimulating Factor 1 Receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 104 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when FIVE PRIME THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →